Published in J Clin Oncol on January 01, 1998
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma (2008) 1.63
Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol (2009) 1.13
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica (2010) 0.91
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant (2013) 0.84
Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. Onco Targets Ther (2010) 0.81
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? Haematologica (2016) 0.76
How I treat mantle cell lymphoma. J Oncol Pract (2007) 0.75
Which treatment for mantle-cell lymphoma patients in 1998? J Clin Oncol (1998) 0.75
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
The B7 and CD28 receptor families. Immunol Today (1994) 6.38
Characterization of a human B lymphocyte-specific antigen. J Immunol (1980) 5.76
Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med (1979) 5.19
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Antigens on human monocytes identified by monoclonal antibodies. J Immunol (1981) 4.67
B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol (1989) 4.61
Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science (1993) 4.45
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Single neurons in prefrontal cortex encode abstract rules. Nature (2001) 4.05
A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature (1980) 3.90
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell (1985) 3.86
B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A (1991) 3.84
Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med (1999) 3.72
Biology and clinical relevance of human natural killer cells. Blood (1990) 3.50
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Isolation of yeast genes with mRNA levels controlled by phosphate concentration. Proc Natl Acad Sci U S A (1980) 3.46
Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol (1991) 3.12
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med (1991) 3.08
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol (2001) 2.97
B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol (1987) 2.92
Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol (1981) 2.86
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A (1993) 2.76
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science (1990) 2.69
Characterization of CTLA-4 structure and expression on human T cells. J Immunol (1993) 2.68
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol (1996) 2.68
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol (1985) 2.66
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood (2000) 2.65
Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature (1992) 2.55
Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 2.51
Stages of B cell differentiation in human lymphoid tissue. J Exp Med (1981) 2.49
B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity (1995) 2.45
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.45
Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy. Int J Radiat Oncol Biol Phys (1996) 2.44
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene (2001) 2.39
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion (1996) 2.37
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest (1981) 2.34
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science (1997) 2.33
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med (1992) 2.26
Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol (2001) 2.20
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest (1993) 2.18
Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science (1994) 2.10
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 2.06
Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology (2007) 2.05
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 2.04
Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A (1993) 2.03
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med (1991) 1.98
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
Monoclonal antibodies defining serologically distinct HLA-D/DR related Ia-like antigens in man. Hum Immunol (1981) 1.94
Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature (1983) 1.93
A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest (1981) 1.93
Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci U S A (1992) 1.92
Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci U S A (1981) 1.91
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest (1997) 1.84
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science (1985) 1.83
CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature (1989) 1.82
Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med (1993) 1.81